https://www.selleckchem.com/pr....oducts/fenebrutinib-
7% in unrestrictive, P = 0.05) but no statistically significant difference in transplant-free survival (33.3% in I/RAS vs 53.5% in unrestrictive, P = 0.11). CONCLUSION The survival disadvantage conferred by prenatally diagnosed severe atrial septal restriction is most pronounced in the neonatal and early infancy period with no detectable difference in late mid-term transplant-free survival in our cohort. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved
Tycka om
Kommentar
Dela med sig
